FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.01 HKD | | 200,000,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - The report from Citi indicates an accelerated trend of original research drugs moving from "in-hospital" to "out-of-hospital" markets, leading to an upward revision of Alibaba Health's (00241) adjusted net profit forecasts for fiscal years 2026 and 2027 by 8% and 12% respectively, reflecting a more optimistic outlook on drug sales [1] Group 1: Financial Projections - Alibaba Health has raised its revenue growth guidance for fiscal year 2026 to 10% to 20%, up from the previous range of 5% to 10% [1] - The adjusted net profit growth guidance has also been increased to 20% to 30%, compared to the earlier forecast of 10% to 20% [1] - The strong sales performance of original and innovative drugs, particularly GLP-1 medications, has contributed to these positive adjustments [1] Group 2: Market Trends - The robust sales data from Alibaba Health and JD Health (06618) confirms the accelerating and sustainable trend of prescription drug outflow [1] - As original and innovative pharmaceutical companies expand new sales channels, online platforms like Alibaba Health and JD Health emerge as the biggest beneficiaries [1] Group 3: Target Price Adjustment - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, while maintaining an "outperform" rating [1]

Core Viewpoint - Alibaba Health (00241) shares rose over 5%, currently up 5.14% at HKD 6.14, with a trading volume of HKD 14.52 billion, following a report from Citi that raised revenue and profit growth guidance for FY2026 due to better-than-expected sales of innovative drugs, particularly GLP-1 drugs [1] Revenue Growth Guidance - Alibaba Health has increased its revenue growth guidance for FY2026 to 10% to 20%, up from the previous 5% to 10% [1] - The adjusted net profit growth guidance has also been raised to 20% to 30%, from the earlier 10% to 20% [1] Sales Performance - Strong sales data from Alibaba Health and JD Health confirm the accelerating trend of prescription drug outflow, which is deemed sustainable [1] - The shift of original and innovative drugs from "in-hospital" to "out-of-hospital" markets benefits online platforms like Alibaba Health and JD Health [1] Profit Forecast Adjustments - Citi has adjusted its net profit forecasts for Alibaba Health for FY2026 and FY2027 upwards by 8% and 12% respectively, reflecting a more optimistic outlook on drug sales [1] - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]

Core Viewpoint - Alibaba Health (00241) shares rose over 5%, reaching HKD 6.14, with a trading volume of HKD 14.52 billion, following an upgrade in revenue and profit growth guidance by Citi [1] Group 1: Financial Guidance - Citi raised Alibaba Health's revenue growth forecast for FY2026 to 10%-20% from the previous 5%-10% [1] - The adjusted net profit growth guidance was also increased to 20%-30% from 10%-20% [1] Group 2: Market Trends - The strong sales performance of original and innovative drugs, particularly GLP-1 medications, exceeded expectations [1] - The trend of prescription drug outflow is accelerating and appears sustainable, with Alibaba Health and JD Health being the primary beneficiaries [1] Group 3: Profit Forecast Adjustments - Based on the accelerated shift of original drugs from "in-hospital" to "out-of-hospital" markets, Citi adjusted Alibaba Health's net profit forecasts for FY2026 and FY2027 upwards by 8% and 12% respectively [1] - The target price for Alibaba Health was raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]

Core Viewpoint - The report from Citi highlights that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10%-20% and adjusted net profit growth guidance to 20%-30%, primarily driven by better-than-expected sales performance of innovative drugs, particularly GLP-1 medications [1] Company Summary - Alibaba Health's strong sales data, along with that of JD Health, confirms the acceleration and sustainability of the trend of prescription drug outflow [1] - The online platforms are identified as the biggest beneficiaries for innovative pharmaceutical companies in expanding new sales channels [1] - Citi has revised its adjusted net profit forecasts for Alibaba Health for fiscal years 2026 and 2027 upwards by 8% and 12% respectively [1] - The target price for Alibaba Health has been increased from HKD 4.8 to HKD 6.5, while maintaining an "Outperform" rating [1]

Core Viewpoint - Credit Suisse reports that Alibaba Health has raised its revenue growth guidance for the fiscal year 2026 to 10% to 20% (previously 5% to 10%) and adjusted net profit growth guidance to 20% to 30% (previously 10% to 20%), primarily due to better-than-expected sales performance of original and innovative drugs, particularly GLP-1 drugs [1] Group 1 - Alibaba Health and JD Health's strong sales data confirm the accelerating and sustainable trend of prescription drug outflow [1] - The acceleration of original drug sales from hospitals to external markets has led to an 8% and 12% upward adjustment in Alibaba Health's adjusted net profit forecasts for fiscal years 2026 and 2027, respectively [1] - The target price for Alibaba Health has been raised from HKD 4.8 to HKD 6.5, maintaining an "outperform" rating [1]

Core Insights - Alibaba Health and LEO Pharma have announced a strategic partnership focused on digital health management and innovative drug accessibility, aiming to enhance patient care and streamline health services [1] - The collaboration marks a significant milestone in the integration of internet platforms with the pharmaceutical industry, emphasizing patient-centered digital health management [1] - Both companies aim to leverage their strengths to improve the management of chronic skin diseases, providing personalized and efficient health management solutions [1] Company Collaboration - The partnership will explore scientific management of post-diagnosis home care scenarios, enhancing the treatment adherence and accessibility of innovative medications [1] - Alibaba Health's CEO highlighted the integration of LEO's innovative drugs with their digital capabilities to facilitate easier treatment adherence for patients [1] - LEO Pharma's executive emphasized the transformative impact of digital technology on healthcare, aiming to provide comprehensive support for patients with skin diseases [1] Project Outcomes - Previous collaborations have yielded significant results, with a notable 30% increase in medication adherence among patients involved in the skin disease management project [2] - Patients participating in chronic disease community management experienced a 3.2 times increase in medication adherence, leading to improved disease control [2] - These outcomes demonstrate the effectiveness of digital interventions in managing chronic skin diseases and provide valuable insights for the industry [2]

Core Viewpoint - Alibaba Health and LEO Pharma have announced a strategic partnership to enhance digital health management and improve accessibility to innovative treatments for skin diseases [1][4]. Group 1: Strategic Partnership - The collaboration focuses on technology-driven medical innovation, comprehensive health management, and improving the accessibility of innovative drugs [1]. - Alibaba Health has a user base of 300 million and has partnered with thousands of pharmaceutical companies globally [3]. - LEO Pharma has been active in China, promoting awareness and standardized treatment for skin diseases like psoriasis and atopic dermatitis, helping over 65 million patients [3]. Group 2: Digital Health Management - The partnership aims to deepen the patient-centered digital health management model, integrating LEO's innovative drugs with Alibaba's digital capabilities [4]. - Previous joint projects have shown significant results, with patient medication adherence increasing by 30% and up to 3.2 times for those in chronic disease community management [3]. - The collaboration will continue to explore scientific management in post-diagnosis home settings, providing smarter, personalized, and efficient health management solutions [5].

Core Viewpoint - Alibaba Health and LEO Pharma have announced a strategic partnership to enhance digital health management and improve accessibility to innovative medications for patients [1][2]. Group 1: Strategic Collaboration - The collaboration will focus on new technology-driven medical innovations, comprehensive health management, and improving the accessibility of innovative drugs [1]. - Alibaba Health has established partnerships with thousands of pharmaceutical companies globally, leveraging its digital capabilities and online channel advantages [1]. - LEO Pharma has been dedicated to promoting scientific understanding and standardized treatment awareness for skin diseases in China, helping over 65 million patients through various initiatives [1]. Group 2: Project Outcomes - Previous collaborations have led to significant results in skin disease management projects, enhancing patient adherence to medication and self-management of diseases [1]. - Data indicates that patient adherence to medication improved by 30% compared to the previous year, with a 3.2 times increase in adherence among patients participating in chronic disease community management [1]. Group 3: Future Directions - The partnership aims to further explore scientific management in post-diagnosis home settings, providing more intelligent, personalized, and efficient health management solutions for patients [2].

Core Viewpoint - Alibaba Health (00241) has signed a 30-month lease agreement for a property in Hangzhou, enhancing its supply chain capabilities and operational efficiency [1] Group 1: Lease Agreement Details - The lease is between Alibaba Health's indirect wholly-owned subsidiary, Alibaba Health Pharmaceutical Chain, and Hangzhou Chuanfu, with a lease term starting from August 28, 2025 [1] - The leased property covers an area of approximately 87,000 square meters [1] Group 2: Strategic Importance - The property is located in the Alibaba Health Pharmaceutical Logistics Park in Tangjiadai Village, which is a key city in East China, specifically Hangzhou [1] - This facility will serve as a major warehouse for storing pharmaceuticals, medical devices, and various health-related products, significantly improving the company's supply chain capabilities and operational efficiency [1] - The company has already established operations in the area and built relationships with local suppliers [1]